Welcome to our dedicated page for Biovie news (Ticker: BIVI), a resource for investors and traders seeking the latest updates and insights on Biovie stock.
BioVie Inc is a clinical-stage biopharmaceutical company developing novel therapies for chronic liver disease and neurodegenerative disorders. The company's news flow primarily focuses on clinical trial updates, regulatory interactions, and scientific presentations related to its two main drug candidates.
The BIV201 program for liver disease generates news around clinical trial progress, regulatory milestone achievements, and patent developments. Updates typically cover trial design discussions with regulatory authorities, patient enrollment progress, and data readouts from ongoing studies evaluating the drug's potential to reduce ascites in cirrhotic patients. Announcements may also address manufacturing developments and formulation optimization efforts.
The bezisterim neurodegenerative disease program produces news related to multiple clinical trials across different indications. Updates frequently include data presentations at major medical conferences, results from completed trial phases, and announcements of new trial initiations. Conference presentations often showcase detailed analyses of cognitive assessments, motor function evaluations, and biomarker data from Alzheimer's and Parkinson's disease studies.
Corporate news includes announcements of strategic partnerships, intellectual property developments, and financing activities that support clinical development programs. The company periodically provides pipeline updates outlining development priorities and timelines for upcoming clinical milestones. Scientific publications in peer-reviewed journals may also generate news coverage when research findings are formally published.
Regulatory news encompasses communications regarding clinical trial design approvals, regulatory designation grants, and interactions with health authorities. These announcements often signal important validation of development approaches and may impact development timelines and regulatory pathways. Patent issuances and intellectual property developments also generate newsworthy announcements that strengthen the company's competitive position.
Investor-focused news includes financial results, corporate presentations, and guidance on upcoming data catalysts. The company participates in healthcare investor conferences and may announce key opinion leader webinars that provide deeper insights into disease areas and drug mechanisms of action.
BioVie Inc. (NASDAQ: BIVI), a clinical-stage company, announced positive findings from its Phase 2 trial for NE3107, aimed at improving cognitive functions in Alzheimer's patients. The study revealed NE3107 may reduce Horvath DNA methylation SkinBlood clock by 3.3 years after 3 months of treatment. Among 23 patients, results indicated significant cognitive enhancement, with 2.2 point improvement on the modified ADAS-Cog12 scale and a reduction in CSF phospho-tau levels. No adverse events were reported, suggesting NE3107's potential in addressing aging-related diseases.
BioVie Inc. (BIVI) announced positive results from two Phase 2 trials evaluating NE3107 for Parkinson's and Alzheimer's diseases. In the Parkinson's trial, patients receiving NE3107 with levodopa achieved a clinically meaningful improvement of over 3 points in motor function compared to levodopa alone. Notably, those under 70 saw a 6-point enhancement. In the Alzheimer's trial, NE3107 improved cognition, showing a 2.1-point gain on the ADAS-Cog12 scale. Additionally, biomarkers related to neuroinflammation decreased without any adverse effects reported.
BioVie Inc. (BIVI) has increased the enrollment target for its Phase 3 trial evaluating NE3107 in Alzheimer’s patients from 316 to 400 due to rapid recruitment and favorable safety data. Over 316 patients are already enrolled, and the company anticipates completing enrollment in two months, with topline results expected by 3Q2023. The trial aims to assess cognition and functional improvement in patients with mild to moderate Alzheimer's disease. The decision to expand enrollment is based on positive early findings and the absence of serious adverse events.
BioVie Inc. (NASDAQ: BIVI) announced that three abstracts from its Phase 2 study of NE3107 for Alzheimer's Disease were accepted for presentation at the 2022 Clinical Trials on Alzheimer’s Disease (CTAD) Annual Meeting, scheduled for November 29-December 2, 2022, in San Francisco, CA.
The presentations include:
- Oral: Neuroimaging Data on December 2 at 11:15am PT
- Posters: Biomarker Assessments on December 1 and Clinical Outcomes on November 29-30.
Results will be disclosed post-conference.
BioVie Inc. (NASDAQ: BIVI), a clinical-stage company, announced its abstract on the hospitalization burden of cirrhosis and ascites at The Liver Meeting 2022 to be held in Washington, DC from November 4-6, 2022. The poster presentation, titled U.S. Hospitalization Burden of Patients with Cirrhosis and Ascites Receiving Paracentesis, is scheduled for November 6, 2022, from 1:00-2:00pm. BioVie develops innovative therapies targeting neurological disorders and advanced liver disease. Notable products include NE3107 for Alzheimer’s and Parkinson’s diseases and BIV201 for treating refractory ascites.
BioVie Inc. (NASDAQ: BIVI) has announced the full enrollment of 44 patients in its Phase 2 trial assessing the effects of NE3107 on Parkinson's disease, with topline data expected in December 2022. The double-blind, placebo-controlled study focuses on both safety and efficacy, particularly analyzing NE3107's interaction with levodopa. Preliminary assessments indicate no drug-related adverse events and suggest a potential efficacy signal. NE3107 is being developed as a treatment for neurodegenerative diseases, and BioVie also has a Phase 3 Alzheimer's trial underway.
BioVie Inc. (NASDAQ: BIVI) announced promising preliminary results from its Phase 2 Alzheimer’s trial for NE3107, reporting an 82% response rate with a mean cognitive improvement of -2.6 points on the ADAS-Cog12 scale. The Phase 3 trial has enrolled over half of the targeted patients and is expected to read out mid-2023. Early data from a Phase 2 Parkinson’s trial is also encouraging, with upcoming data readouts anticipated across various trials within the next 12 months.
BioVie Inc. (NASDAQ: BIVI) announced participation in Cantor Fitzgerald’s Neurology & Psychiatry Conference on October 6-7, 2022, in San Francisco. The management team will be involved in a panel discussion titled Wave of innovation for Alzheimer’s disease on October 7 at 12:00 PM ET. The company is advancing drug therapies targeting Alzheimer’s and Parkinson’s diseases through its lead candidate NE3107. Additionally, BioVie's BIV201 is in a Phase 2 study for liver disease, with anticipated top-line results due in mid-2023.
BioVie Inc. (NASDAQ: BIVI) is set to feature in an interview on The RedChip Money Report, airing on Bloomberg TV on September 17, discussing advancements in clinical research. CEO Cuong Do will outline the promising top-line results from a Phase 2 study of NE3107 for Alzheimer's Disease, along with updates on ongoing Phase 3 and Phase 2 trials related to Alzheimer's and Parkinson's diseases, respectively. The company is focusing on addressing unmet medical needs in chronic liver and neurodegenerative disorders, with significant milestones expected soon.
BioVie (NASDAQ: BIVI) has released significant updates from its Phase 2 clinical trial regarding NE3107 for Alzheimer’s Disease (AD). The trial demonstrated that a vast majority of patients experienced notable improvements in daily abilities and cognition, with 82% of participants showing a decrease in ADAS-Cog12 scores (p=0.0046). Moreover, NE3107 treatment correlated with reductions in TNF-a, suggesting potential neuroinflammation benefits. No adverse events were reported, and the company plans to present detailed results at the upcoming CTAD 2022 Annual Conference.
FAQ
What is the current stock price of Biovie (BIVI)?
What is the market cap of Biovie (BIVI)?
